InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
Vancouver, BC – April 30, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and… Read More


